In vitro inhibition of Ras-Raf association by short peptides.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  1998-06-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/BBRC.1998.8746PMID 9636675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p120 Ras GTPase-activating Protein Interacts with Ras-GTP through Specific Conserved Residues*

  1996cited by this paper
• Ras‐effector interactions, the problem of specificity

  1995cited by this paper
• The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue

  1995cited by this paper
• Identification of the sites of interaction between c-Raf-1 and Ras-GTP.

  1995cited by this paper
• Regulation of Ras-mediated signalling: more than one way to skin a cat.

  1995cited by this paper
• Raf meets Ras: completing the framework of a signal transduction pathway.

  1994cited by this paper
• Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues

  1994cited by this paper
• The many roads that lead to Ras.

  1993cited by this paper
• Identification of amino acid residues required for Ras p21 target activation

  1991cited by this paper
• ras genes.

  1987cited by this paper
• Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

  1984cited by this paper

• Peptide inhibitors: Breaking cancer code.

  2025cites this paper
• Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

  2023cites this paper
• Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors.

  2021cites this paper
• How we responded to reviewers’ comments: Novel, Provable Algorithms for Efficient Ensemble-Based Computational Protein Design and Their Application to the Redesign of the c-Raf-RBD:KRas Protein-Protein Interface

  2020cites this paper
• Ras functional proximity proteomics establishes mTORC2 as new direct ras effector

  2019influential citation
• Development of split luciferase complementation probes sensing KRAS/effector interaction

  2019cites this paper
• Targeting Ras with Macromolecules.

  2018cites this paper
• The RAS-Effector Interaction as a Drug Target.

  2017cites this paper
• The most oncogenic Ras isoform: specific insights into K-Ras structure, dimerization, and targeting.

  2017influential citation
• Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V).

  2017cites this paper
• Direct Inhibitors of Ras-Effector Protein Interactions.

  2016cites this paper
• Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides.

  2015cites this paper
• Direct Modulation of Small GTPase Activity and Function.

  2015cites this paper
• Significance of Ras Signaling in Cancer and Strategies for its Control

  2015cites this paper
• Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects

  2015cites this paper
• Direkte Modulation von Aktivität und Funktion kleiner GTPasen

  2015cites this paper
• Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.

  2014cites this paper
• Small-molecule modulation of Ras signaling.

  2014cites this paper
• Inhibition of Ras-Effector Interaction by Cyclic Peptides.

  2013cites this paper
• State 1(T) inhibitors of activated Ras.

  2013cites this paper
• Metall‐Bis(2‐picolyl)amin‐Komplexe als Zustand‐1(T)‐Inhibitoren für aktiviertes Ras‐Protein

  2012cites this paper
• Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated Ras protein.

  2012cites this paper
• Zinc(II)cyclen–peptide conjugates interacting with the weak effector binding state of Ras

  2011cites this paper
• Identification and Characterization of a Peptidic Ligand for Ras

  2010cites this paper
• In Vitro Selection of a DNA-Templated Small-Molecule Library Reveals a Class of Macrocyclic Kinase Inhibitors

  2010cites this paper
• Therapeutic peptides for cancer therapy. Part I – peptide inhibitors of signal transduction cascades

  2009cites this paper
• Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein

  2009cites this paper
• [What is a targeted therapy? The view of the biologist].

  2007cites this paper
• Entwicklung neuer Inhibitoren für das Ras-Protein und dessen onkogene Mutanten auf Basis von Cyclenderivaten

  2007cites this paper
• Application des librairies de codons dégénérés à l'étude du mécanisme de repliement et de la stabilisation de la structure du domaine liant ras de Raf

  2006cites this paper
• Proteins of the Ras pathway as novel potential anticancer therapeutic targets

  2004cites this paper
• Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.

  2004cites this paper
• [Recent advances in pharmacogenomics in oncology].

  2004cites this paper
• Peptides with anticancer use or potential

  2003cites this paper
• Synthesis and biological evaluation of cycloalkylidene carboxylic acids as novel effectors of Ras/Raf interaction.

  2002cites this paper
• The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia

  2002cites this paper
• Protein farnesyltransferase inhibitors.

  2002cites this paper
• RAS Binding Compounds

  2002cites this paper
• Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells

  2002cites this paper
• Prospects for anti‐ras drugs

  2002cites this paper
• Design of inhibitors of Ras--Raf interaction using a computational combinatorial algorithm.

  2001cites this paper
• Gas6 Induces Growth, β-Catenin Stabilization, and T-Cell Factor Transcriptional Activation in Contact-Inhibited C57 Mammary Cells

  2001cites this paper
• The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors.

  2000cites this paper
• Ras-A Molecular Switch Involved in Tumor Formation.

  2000cites this paper
• RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of galphao.

  2000cites this paper
• Gas 6 Induces Growth , b-Catenin Stabilization , and T-Cell Factor Transcriptional Activation in Contact-Inhibited C 57 Mammary Cells

  2000cites this paper
• Ras – ein molekularer Schalter bei der Tumorentstehung

  2000cites this paper
• Proteins of the Ras pathway as novel potential anticancer therapeutic targets

  1999cites this paper
• RGS 14 is a novel Rap effector that preferentially regulates the GTPase activity of G α o

  year unknowncites this paper